Stated plainly: eGFR · orforglipron.
I can predict the outcome but I cannot explain it, which means I will get the next case wrong.
I would like to know how confident the field actually is about this.
Can someone derive this rather than assert it?
Worth being precise here: this is one of the areas where the trend across several measurements is far more informative than any single result.
Alanine aminotransferase is relatively liver-specific; aspartate aminotransferase is also present in muscle, heart and red cells. A raised AST with a normal ALT after heavy resistance training is usually muscle, and creatine kinase settles the question.
| Quantity | Value | Derivation |
|---|---|---|
| Control-arm event rate | 8.0 % | From the trial table, not the abstract |
| Hazard ratio | 0.80 | Reported |
| Treated event rate | 6.4 % | 8.0 × 0.80 |
| Absolute risk reduction | 1.6 pp | 8.0 − 6.4 |
| Number needed to treat | 63 | 1 ÷ 0.016 |
| Relative risk reduction | 20 % | 1 − 0.80 |
The last two rows describe the same finding. Only one of them is used in headlines.
More usefully, very rapid weight loss can transiently worsen liver biochemistry, which is one of several arguments against pursuing the steepest possible trajectory.
Hy's law and its variants are the standard framework for identifying drug-induced liver injury in trials and are why bilirubin is measured alongside transaminases rather than instead.
The caveat is direct: rising liver enzymes with jaundice, dark urine or right-upper-quadrant pain is a same-day clinical problem, not a forum question.
Get a baseline before you start anything, because it converts an uninterpretable result into an interpretable one for the cost of one blood draw.
edited 13 Jul 2024 by fib4_reader — tightened the wording; no substantive change
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe relevant caution is that a rapid rise, particularly with bilirubin, is a different event from a stable mild elevation and needs handling differently.
Gamma-glutamyl transferase is sensitive and unspecific: it rises with alcohol, with several medications and with fatty liver, and an isolated elevation rarely changes anything on its own.
It helps to be literal here: an isolated result three weeks after starting anything is difficult to interpret. A baseline taken before starting makes the same result trivially interpretable, which is the argument for baselines.
Population data show a substantial fraction of adults with mild transaminase elevation attributable to hepatic steatosis, which sets the base rate against which any new finding should be read.
Attributing an enzyme change to a compound requires a baseline, and most people asking have not got one.
Read the pattern before the magnitude, and the magnitude in multiples of the upper limit.
Answer first: mild transaminase elevation is common in this population before any drug is involved, and the usual cause is hepatic steatosis rather than anything acute.
Reference upper limits around forty units per litre for ALT are conventional rather than physiological; several groups have argued for limits closer to thirty for men and twenty-five for women.
Hy's law describes the combination that matters: transaminases above three times the upper limit together with bilirubin above twice the upper limit and no cholestatic explanation. That combination is a signal; isolated mild transaminase elevation is not.
Research-use material of unknown content is an unquantifiable variable in any such attribution.
Isolated mild elevation is common and usually improves with weight loss.
The honest answer is that mild elevation is very common, that it usually improves with weight loss, and that the exceptions are the reason anyone checks.
Weight loss of ten per cent or more typically reduces transaminases substantially in people whose elevation was driven by hepatic fat, which is the majority of mild elevations in this population.
Nothing here is medical advice. An abnormal result needs somebody who can take a history and examine you.
New training, alcohol and over-the-counter products first. Then the interesting hypotheses.
The short version: enzymes in this class usually fall as weight falls, and a rise is a reason to look for a cause rather than to assume a drug effect.
Creatine kinase, alkaline phosphatase and bilirubin together tell you which compartment the abnormality is in, and ordering the transaminases alone throws that information away.
Transaminases plus bilirubin plus alkaline phosphatase, or you have not measured enough to conclude anything.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.